Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion. The German Institute for Quality and ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined in an early benefit assessment whether faricimab offers patients benefits over ranibizumab or aflibercept.